about
AcromegalySomatostatin analogues for treatment of enterocutaneous fistulaOctreotide for the treatment of chylothorax in neonatesSomatostatin analogues for acute bleeding oesophageal varicesOctreotide for the treatment of chylothorax in neonatesSomatostatin analogues for acute bleeding oesophageal varicesA multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretionPasireotide: a novel treatment for patients with acromegalyLong-term medical treatment in congenital hyperinsulinism: a descriptive analysis in a large cohort of patients from different clinical centersFrom targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumorsConformational diversity in contryphans from Conus venom: cis-trans isomerisation and aromatic/proline interactions in the 23-membered ring of a 7-residue peptide disulfide loopClinical utility of lanreotide AutogelĀ® in gastroenteropancreatic neuroendocrine tumorsQuantitative and functional expression of somatostatin receptor subtypes in human thymocytesSynthesis, conformational analysis and bioactivity of Lan-7, a lanthionine analog of TT-232Role of somatostatin-14 and its analogues in the management of gastrointestinal fistulae: clinical dataGrowth hormone and the heart.Refractory thrombocytopenia responds to octreotide treatment in a case of evans syndrome with gastric neuroendocrine tumor.Successful treatment of protein-losing enteropathy induced by intestinal lymphangiectasia in a liver cirrhosis patient with octreotide: a case report.Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.Is presurgical treatment with somatostatin analogs necessary in acromegalic patients?A primary intestinal lymphangiectasia patient diagnosed by capsule endoscopy and confirmed at surgery: a case report.Growth hormone overproduction in a patient with multiple endocrine neoplasia type I.Central injection of the stable somatostatin analog ODT8-SST induces a somatostatin2 receptor-mediated orexigenic effect: role of neuropeptide Y and opioid signaling pathways in rats.Current management of acromegaly.Somatostatin modulates insulin-degrading-enzyme metabolism: implications for the regulation of microglia activity in ADOctreotide LAR treatment throughout pregnancy in an acromegalic woman.Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patientsManagement of gastrointestinal angiodysplastic lesions (GIADs): a systematic review and meta-analysis.Systematic review: the use of somatostatin or octreotide in refractory diarrhoea.Bench-to-bedside review: Antidotal treatment of sulfonylurea-induced hypoglycaemia with octreotide.The place of pegvisomant in the management of acromegaly.Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors.Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma.Pancreatic surgical complications--the case for prophylaxisCongenital pulmonary lymphangiectasiaAcromegaly: a new therapy.Update in clinical toxicology.Advances in diagnosis and therapy of neuroendocrine tumors.Review of the clinical, histological, and molecular aspects of pancreatic endocrine neoplasms.Somatostatin analogs and radiopeptides in cancer therapy.
P2860
Q21202912-2CDECAEF-FE8D-43BD-B2A9-B9F60B8F81B3Q24198107-CB4679EE-38EA-4BC8-AAB2-5EE736FCFBDAQ24235464-D3FE4DCF-159D-4A66-8540-F7CE74A03265Q24242106-236F2848-0FB3-462C-B8B8-053E2374784BQ24243477-13D3EBDF-AEA4-45F8-9C17-C7BC7037DDA0Q24244801-13DE98D7-9F81-4887-8A0B-3F27BE9A41A5Q24678786-4860146C-CDE7-4527-92D9-C4125B7138A4Q26774437-B8C1EF2F-C2EA-4066-BEAB-A7121A41FE33Q26775424-C6742EC2-3D26-4D9B-B2D5-79D3C47864C7Q26822011-0CFB7D49-534B-45A4-A9EE-90B98A71131FQ27687104-0EE65F45-3B6B-424C-B8D2-CED41562F060Q28069632-0247788E-2B53-4C41-BD8E-4EE9D2A038F1Q28206900-A553EE0A-264B-4BF8-B9F3-B5FBCB2E38FCQ28370497-5EE1C19C-94C7-4B24-9898-373B7420A052Q30677685-F95A5427-ECE4-42CC-BBE0-2DD746B6DE5FQ32026861-8DDC80F4-1388-44E2-9C3E-CEBC5E6AB5E3Q33410042-969F6780-EF50-496D-BF4B-17219E855189Q33631645-85CA7151-CA51-46AB-ABD1-07A4E352AE0AQ33702355-BE41A3DA-FC94-4A6B-B491-6860AA9E790AQ33858637-C883713B-FD55-46CB-B58E-7C5B6E081039Q34098974-3C81C252-E0EB-4748-ACF5-23501305030EQ34129540-4E5537E7-B856-47CC-A9B9-02644E0F7B76Q34132339-E43DC101-3AD6-464F-838A-C4A786325BF7Q34182034-305EC951-2BA6-4C92-B3A8-DAB29A245A50Q34235168-BEE8623E-125F-47FC-8304-0BBF6F5DEFBCQ34394102-0937A6B3-27D5-4EE8-813F-B890CB2B36CBQ34410241-19365E12-60A5-4CFB-A2B4-4C5D00C8EAEAQ34410798-3395825D-3DAE-40CA-835A-E22FE2A19734Q34458946-BC25F699-1F3C-438E-A6AD-2B9DEE1B62ABQ34480831-BE8E8889-D433-498E-80C4-288685204AC1Q34481733-6AFFCF61-B3B8-4424-9059-EE758750AB86Q34498450-150C8540-9A52-45F1-8373-A8F0CFDC4532Q34528281-BDE5368E-5081-4B83-8DBB-53C659CA7EAAQ34552348-002FE911-B7D2-478E-A016-952D5A917BCFQ34572220-99FBCA42-0207-4C9C-924E-C6D12E07F31FQ34713607-72807BED-823E-43C2-99DA-46B73F51C23AQ34714524-A2CBEACD-C41F-460E-A049-80D08AE3FF99Q34734203-D8450C9D-54EA-4931-9889-86D5BA063C18Q34810946-03CA03AD-562D-4A4B-AF3A-25161EC0ECADQ34972896-8C1536A3-29DB-479B-8C78-055E7C7E2946
P2860
description
1996 nĆ® lÅ«n-bĆ»n
@nan
1996幓ć®č«ę
@ja
1996幓č«ę
@yue
1996幓č«ę
@zh-hant
1996幓č«ę
@zh-hk
1996幓č«ę
@zh-mo
1996幓č«ę
@zh-tw
1996幓č®ŗę
@wuu
1996幓č®ŗę
@zh
1996幓č®ŗę
@zh-cn
name
Octreotide.
@en
type
label
Octreotide.
@en
prefLabel
Octreotide.
@en
P2093
P1476
Octreotide.
@en
P2093
Hofland LJ
Lamberts SW
de Herder WW
van der Lely AJ
P304
P356
10.1056/NEJM199601253340408
P407
P577
1996-01-01T00:00:00Z